{"id":"W3158712737","doi":"10.1038/s41591-021-01317-6","title":"An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer","year":2021,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Durvalumab; Biomarker; Medicine; PARP inhibitor; Bladder cancer; Oncology; Cancer research; Cancer; Targeted therapy; Urothelium; Internal medicine; Immunotherapy; Biology; Nivolumab; Poly ADP ribose polymerase; DNA; Urinary bladder","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006962811,0.0006050691,0.00107258,0.0002308529,0.0002040972,0.0008549768,0.0005144615,0.0006280332,0.001330788],"category_scores_gemma":[0.0004327272,0.0003056728,0.0006483016,0.000251125,0.0004252807,0.0005339992,0.0003078666,0.001474774,0.0002224021],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007438936,"about_ca_system_score_gemma":0.0008685093,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000903405,"about_ca_topic_score_gemma":0.001315524,"domain_scores_codex":[0.9997615,0.00006584937,0.000008511507,0.00005573379,0.00003719894,0.00007121828],"domain_scores_gemma":[0.999861,0.00002326466,0.0000293029,0.00002307784,0.00001304641,0.00005030661],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1471337,0.03013923,0.01117988,0.0006684926,0.001416523,0.0006419053,0.0002904017,0.009548313,0.6035621,0.001503639,0.002548521,0.1913673],"study_design_scores_gemma":[0.05954404,0.6250215,0.02945321,0.00008508417,0.002469595,0.001656675,0.000321063,0.02551633,0.2377415,0.001016864,0.01703679,0.0001373378],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996963,0.0009849322,0.0008077872,0.0001761654,0.00009049798,0.000174925,0.0001454738,0.00002665448,0.0006305873],"genre_scores_gemma":[0.9964915,0.0007659256,0.001415682,0.0002124581,0.00003759867,0.0001442981,0.0001962504,0.00001404037,0.0007222394],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001330788,"threshold_uncertainty_score":0.005397379,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01968541919565534,"score_gpt":0.3248717961462149,"score_spread":0.3051863769505595,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}